Published in Oncology Business Week, April 3rd, 2005
Peter Wulff, president and CEO, commented, "We view the biodefense market as any other market, where if you want to be a leader you have to invest in your own future. This latest decision is part of our long-term strategy that we embarked upon in 1998 to develop and supply a safe smallpox vaccine.
he increased interest that we have now seen in our Imvamune smallpox vaccine from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.